

# Danilo Villalta

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9603374/publications.pdf>

Version: 2024-02-01

7  
papers

140  
citations

1937685

4  
h-index

1720034

7  
g-index

8  
all docs

8  
docs citations

8  
times ranked

365  
citing authors

#	ARTICLE	IF	CITATIONS
1	New-Generation Quantitative Immunoassays for SARS-CoV-2 Antibody Detection: Need for Harmonization. <i>Annals of Laboratory Medicine</i> , 2022, 42, 113-116.	2.5	3
2	Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2. <i>Clinica Chimica Acta</i> , 2022, 524, 11-17.	1.1	16
3	Validation Parameters of Patient-Generated Data for Digitally Recorded Allergic Rhinitis Symptom and Medication Scores in the @IT.2020 Project: Exploratory Study. <i>JMIR MHealth and UHealth</i> , 2022, 10, e31491.	3.7	1
4	Diagnostic performance of an automated chemiluminescence immunoassay for SARS-CoV-2 IgG and IgM antibodies detection: A real life experience. <i>Practical Laboratory Medicine</i> , 2021, 25, e00227.	1.3	6
5	Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease. <i>Immunologic Research</i> , 2021, 69, 576-583.	2.9	34
6	QuantiFERON-TB Gold Plus: High Qualitative and Quantitative Agreement between Enzyme-Linked Immunosorbent Assay (ELISA) and Chemiluminescence Immunoassay (CLIA). <i>Journal of Clinical Microbiology</i> , 2020, 58, .	3.9	3
7	Serological Assays for SARS-CoV-2 Infectious Disease: Benefits, Limitations and Perspectives. <i>Israel Medical Association Journal</i> , 2020, 22, 203-210.	0.1	77